Does Wegovy Help with Blood Pressure — and How Much?

Does the weight loss itself explain the blood pressure drop?

Largely, yes. When the body sheds a significant proportion of excess weight, the heart faces less resistance pumping blood around a smaller mass of tissue. Adipose tissue (particularly visceral fat around the abdomen) is metabolically active and contributes to systemic inflammation, arterial stiffness and raised blood pressure over time. Reduce it, and cardiovascular strain eases. The STEP 1 trial, published in the New England Journal of Medicine, showed an average body weight reduction of around 15% at 68 weeks in adults taking semaglutide 2.4mg, and accompanying reductions in systolic blood pressure were consistently reported across the STEP programme. Most researchers attribute the majority of the blood pressure effect to the weight change, with a smaller possible direct contribution from GLP-1 receptor activation on the kidneys and vasculature, though the evidence for that direct pathway is less settled.

What matters practically: the blood pressure benefit accrues gradually, tracking the weight loss. It is not immediate and it is not uniform. People who lose more weight tend to see larger reductions; those who are already normotensive may see little measurable change at all.

Is there a separate cardiovascular case for Wegovy beyond weight loss?

There is. The SELECT trial enrolled over 17,000 adults with established cardiovascular disease and obesity but without type 2 diabetes, and found that semaglutide 2.4mg reduced the rate of major adverse cardiovascular events (heart attack, stroke and cardiovascular death) by around 20% over roughly three years. The MHRA has authorised Wegovy for this cardiovascular indication separately from its weight-management licence, and the NHS semaglutide medicines page reflects both uses. This is a different regulatory pathway from the blood pressure question, but it reinforces that the cardiovascular effects of semaglutide extend beyond what the scales show.

For UK readers wondering about Wegovy and high blood pressure specifically, the honest answer is this: it is not licensed as a blood pressure medicine, and it should not be started for that reason alone. But for someone who qualifies for Wegovy on weight and eligibility grounds and also has hypertension, the evidence on how Wegovy affects blood pressure suggests the treatment may help on both fronts. A prescriber is the right person to weigh that up for any individual.

Should you adjust your blood pressure medication when starting Wegovy?

This is a question our prescribers hear regularly, and the short answer is: not on your own initiative. As weight falls and blood pressure responds, there is a real possibility that antihypertensive medicines you are already taking become relatively too strong, leading to readings that dip lower than intended. Symptoms like dizziness on standing, lightheadedness or feeling faint can be signs of this. None of that means you should reduce or stop your blood pressure medication, it means you should tell your prescriber what is happening so they can review the dose. The NHS advises that anyone taking medicines that already lower blood pressure should flag this before starting a GLP-1 medicine, so monitoring can be planned in from the start. That conversation is part of what happens at a thorough clinical assessment.

One practical habit worth building: check your blood pressure at a pharmacy machine or at home before each monthly repeat, and note the reading. It takes under a minute and gives your prescriber a running picture rather than a single snapshot. If you have any concerns, our team is available seven days a week. You can also read more about the broader cardiovascular effects of semaglutide in our dedicated coverage of that topic.

Who actually qualifies for Wegovy in the UK, and does hypertension count?

Wegovy is licensed for adults with a BMI of 30 or above, or 27 or above if at least one weight-related condition is present. Hypertension (high blood pressure) is explicitly recognised as one of those weight-related conditions under UK clinical guidance, which means it can contribute to eligibility at the lower BMI threshold. NICE's appraisal of semaglutide (TA875) covers NHS access, that route involves specialist weight management services and typically involves waiting. Private treatment through a regulated online pharmacy is the alternative for those who meet the clinical criteria but cannot access NHS provision quickly or do not meet the stricter NHS thresholds.

Eligibility is never decided by BMI alone. A prescriber reviews the full clinical picture: current medications, existing conditions, what has been tried before, and whether the treatment is appropriate and safe for this specific person. If you are considering Wegovy and want to understand whether it could work for your situation, including its potential effects on blood pressure, our Wegovy overview covers the full picture, or you can start a free consultation to speak with a GPhC-registered prescriber directly. For context on what private treatment typically costs, our Wegovy price comparison page sets out the landscape honestly.